
Immunic Investor Relations Material
Latest events

Q3 2024
Immunic
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Immunic Inc
Access all reports
Immunic Inc. is a clinical-stage biopharmaceutical company, developing a pipeline of selective oral immunology therapies. The company’s lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. Its other programs are IMU-935 for the restoration of the intestinal barrier in patients suffering from diseases such as inflammatory bowel disease; IMU-856 for restoration of the intestinal barrier function in patients suffering from diseases such as inflammatory bowel disease with diarrhea; and an anti-inflammatory intravenous formulation being developed to treat acute kidney injury.
Key slides for Immunic Inc


Q1 2024
Immunic Inc


Q2 2024
Immunic Inc
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
IMUX
Country
🇺🇸 United States